Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 10/20 | 0.48 |
| ▸ | CTSL | P07711 | 2/20 | 0.48 |
| ▸ | CTSB | P07858 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA7 | P43166 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | PREP | P48147 | 1/20 | 0.40 |
| ▸ | CTSS | P25774 | 2/20 | 0.39 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18534563 | 1.00 | CTSK (0.48) | CTSKCTSLCTSBCA1CA2 | |
| SCHEMBL7510900 | 1.00 | CTSK (0.48) | CTSKCTSLCTSBCA1CA2 | |
| SCHEMBL28669035 | 0.98 | CTSK (0.47) | CTSKCTSLCTSBCA1CA2 | |
| SCHEMBL21125085 | 0.98 | CTSK (0.47) | CTSKCTSLCTSBCA1CA2 | |
| SCHEMBL18215140 | 0.98 | CTSK (0.47) | CTSKCTSLCTSBCA1CA2 | |
| Ammonia Solution, Strong SCHEMBL4701521 | 0.98 | CTSK (0.47) | CTSKCTSLCTSBCA1CA2 | |
| SCHEMBL4824903 | 0.98 | CTSK (0.47) | CTSKCTSLCTSBCA1CA2 | |
| SCHEMBL4703911 | 0.98 | CTSK (0.47) | CTSKCTSLCTSBCA1CA2 | |
| SCHEMBL4773114 | 0.88 | CA1 (0.46) | CTSKCTSLCTSBCA1CA2 | |
| SCHEMBL357027 | 0.86 | CTSK (0.49) | CTSKCTSLCTSBCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9238657-B2 | Cephalosporin having catechol group | SHIONOGI & CO., LTD. (JP) | 2016-01-19 | — | — | US | disclosed |
| EP-2341053-B1 | CEPHALOSPORIN HAVING CATECHOL GROUP | SHIONOGI & CO (JP) | 2016-01-13 | — | — | EP | disclosed |
| US-20110190254-A1 | CEPHALOSPORIN HAVING CATECHOL GROUP | SHIONOGI & CO., LTD. (JP) | 2011-08-04 | — | — | US | disclosed |
| EP-2341053-A1 | CEPHALOSPORIN HAVING CATECHOL GROUP | Shionogi & Co., Ltd. (JP) | 2011-07-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190254-A1 | CEPHALOSPORIN HAVING CATECHOL GROUP | NRDC, LUC7L2, NR0B1 | CTSK 1800/4885CTSL 711/4885CTSB 1772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.